Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.75 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 4/20 | 0.64 |
| ▸ | INSR | P06213 | 4/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.64 |
| ▸ | CDK2 | P24941 | 4/20 | 0.64 |
| ▸ | PLK1 | P53350 | 4/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651928 | 1.00 | EGFR (0.75) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL12225357 | 0.91 | EGFR (0.61) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL6954796 | 0.91 | EGFR (0.84) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL6959487 | 0.91 | EGFR (0.66) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL3702763 | 0.90 | EGFR (0.77) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL19121111 | 0.90 | EGFR (0.67) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL23127803 | 0.88 | ERBB2 (0.65) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL20436802 | 0.88 | EGFR (0.65) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL20220592 | 0.88 | ERBB2 (0.65) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL6960054 | 0.88 | EGFR (0.65) | EGFRERBB2ERBB4GAKABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3574906-B1 | SOLID PREPARATION COMPRISING QUINAZOLINE DERIVATIVE | SHIONOGI & CO (JP) | 2024-07-03 | — | — | EP | disclosed |
| EP-3330267-B1 | SALT OF QUINAZOLINE DERIVATIVE OR CRYSTAL THEREOF, AND METHOD FOR PRODUCING SALT OF QUINAZOLINE DERIVATIVE OR CRYSTAL THEREOF | SHIONOGI & CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-10953016-B2 | Solid dosage form containing quinazoline derivative | SHIONOGI & CO., LTD. (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20190256506-A1 | SALTS OF QUINAZOLINE DERIVATIVE OR CRYSTALS THEREOF, AND THE PROCESS FOR PRODUCING THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-10329285-B2 | Salts of quinazoline derivative or crystals thereof, and the process for producing thereof | SHIONOGI & CO., LTD. (JP) | 2019-06-25 | — | — | US | disclosed |
| US-20180215744-A1 | SALTS OF QUINAZOLINE DERIVATIVE OR CRYSTALS THEREOF, AND THE PROCESS FOR PRODUCING THEREOF | SHIONOGI & CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20180215744-A1 | SALTS OF QUINAZOLINE DERIVATIVE OR CRYSTALS THEREOF, AND THE PROCESS FOR PRODUCING THEREOF | SHIONOGI & CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| EP-3330267-A1 | SALT OF QUINAZOLINE DERIVATIVE OR CRYSTAL THEREOF, AND METHOD FOR PRODUCING SALT OF QUINAZOLINE DERIVATIVE OR CRYSTAL THEREOF | Shionogi&Co., Ltd. (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-9951051-B2 | Process for producing alkynylketone derivative | SHIONOGI & CO., LTD. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9951051-B2 | Process for producing alkynylketone derivative | SHIONOGI & CO., LTD. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| EP-2374801-A1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1854789-A1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
| EP-1854789-A1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953016-B2 | Solid dosage form containing quinazoline derivative | RAB5C, MAP1LC3C, TBC1D5 | EGFR 3987/4885ERBB2 3948/4885ERBB4 3894/4885 |
| US-20180215744-A1 | SALTS OF QUINAZOLINE DERIVATIVE OR CRYSTALS THEREOF, AND THE PROCESS FOR PRODUCING THEREOF | NQO2, SQLE, CYP3A5 | EGFR 3993/4885ERBB2 4104/4885ERBB4 3934/4885 |
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | ABL1, MAP2K5, MAP2K2 | EGFR 213/4885ERBB2 42/4885ERBB4 86/4885 |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | EGFR 2/4885ERBB2 1/4885ERBB4 5/4885 |
| US-20190256506-A1 | SALTS OF QUINAZOLINE DERIVATIVE OR CRYSTALS THEREOF, AND THE PROCESS FOR PRODUCING THEREOF | NQO2, SQLE, CYP3A5 | EGFR 3993/4885ERBB2 4104/4885ERBB4 3934/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | EGFR 2/4885ERBB2 1/4885ERBB4 5/4885 |
| US-10329285-B2 | Salts of quinazoline derivative or crystals thereof, and the process for producing thereof | NQO2, SQLE, CYP3A5 | EGFR 3993/4885ERBB2 4104/4885ERBB4 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.